Latest Revenue Growth News

Medicare contractor Novitas plans to convene an expert panel in early 2026 to review coverage for Pacific Edge’s Cxbladder Triage test following the 2025 update to the American Urological Association microhematuria guideline.

PolyNovo’s NovoSorb BTM, combined with negative pressure wound therapy, significantly accelerates healing of large post-surgical diabetic foot wounds, according to new clinical trial data.

4DMedical confirms its partnership with AstraZeneca in Brazil and announces a new contract supporting Australia’s National Lung Cancer Screening Program, signaling strategic growth in respiratory imaging.

IODM Limited reports a striking 227% year-on-year revenue surge in its UK Education segment for the first two months of FY26, signaling robust momentum ahead of a key invoicing period.

Metcash Limited reported solid FY25 results with revenue up 7.2% to $19.5 billion and EBITDA rising 8.6%, driven by growth in Food and resilience in Liquor despite Hardware challenges. Strategic mergers and ESG progress position the company for accelerated growth in FY26.

Nanoveu Limited reveals significant progress in its ECS-DoT system-on-chip technology, showcasing a 60% average increase in drone flight endurance and advancing production with TSMC’s 16nm process. The company’s latest investor webinar highlights its growing OEM partnerships and disruptive edge AI capabilities.

AdNeo Limited has expanded its footprint in the vocational education sector by acquiring Aspire Learning Resources, adding valuable content and partnerships to its Catapult platform.

Elixinol Wellness has raised $2.5 million through a well-supported placement and appointed industry veteran Gavin Evans as strategic advisor to drive its next phase of growth and operational reset.

Rewardle Holdings reported a modest revenue increase for FY25 but saw its loss more than double, driven by investments in AI-powered MedTech associate CloudHolter and expanded platform initiatives.

Frontier Digital Ventures reported a 5% decline in revenue but a striking 71% jump in EBITDA for the first half of 2025, driven by margin expansion and operational efficiencies across its classifieds marketplaces in emerging regions.

Orthocell Limited reports an 81.1% overall treatment success rate from its Remplir Real World Evidence study, reinforcing the product’s safety and efficacy as it expands sales in the US and prepares regulatory submissions for the EU and UK.

Mayne Pharma has publicly refuted recent media claims about plans to close its Salisbury manufacturing site, clarifying its position amid ongoing regulatory scrutiny of its Scheme transaction with Cosette.